查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016969

兽用和动物疫苗市场：2026-2032年全球市场预测（按产品类型、给药途径、目标疾病、技术平台、价态、动物类型、分销管道和最终用户划分）

Veterinary/Animal Vaccines Market by Product Type, Route Of Administration, Disease Indication, Technology Platform, Valency, Animal Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，兽药和动物疫苗市场价值将达到 150.5 亿美元，到 2026 年将成长到 160.5 亿美元，到 2032 年将达到 240.1 亿美元，复合年增长率为 6.89%。

主要市场统计数据
基准年 2025 150.5亿美元
预计年份：2026年 160.5亿美元
预测年份 2032 240.1亿美元
复合年增长率 (%) 6.89%

对兽用疫苗市场进行全面概述，揭示影响策略的关键驱动因素、相关人员的角色、技术进步以及与监管的互动。

兽用疫苗产业目前正经历一场结构性变革，这场变革正在改变科学范式、商业策略以及生产者和服务供应商的企业发展。来自研究机构、临床机构、畜牧企业和监管机构的相关人员团结一致，致力于改善疾病控制、提升动物福利和建立具有韧性的供应链。随着科学基础的通用扩展，包括先进的免疫学平台和数位健康工具的出现，疫苗研发者和经销商的角色正在从单纯的产品供应商转变为提供端到端预防和监测解决方案的综合合作伙伴。

突破性的科学突破、平台创新以及相关人员优先事项的转变如何重新定义跨物种疫苗的开发、供应和部署。

过去十年，整个动物健康领域经历了数次变革性变化，这些变化正在重塑疫苗的发现、生产、供应和部署方式。其中一项关键的科学转变是平台技术的成熟，这些技术能够加速抗原发现并实现模组化疫苗建构。这些平台缩短了研发週期，并能够对新出现的病原体做出快速反应。同时，精准畜牧业和数位监测系统正在产生更高解析度的流行病学数据，以前所未有的速度建立回馈迴路，从而为疫苗设计和部署策略提供资讯。

分析 2025 年美国关税政策对动物疫苗供应链、製造地选择、价格趋势和全球贸易模式的累积影响。

美国2025年关税政策的调整进一步加剧了贸易的复杂性，对全球供应链和动物保健产业的筹资策略产生了连锁反应。这种累积影响推高了疫苗生产中使用的生物原料、特殊试剂和设备的进口成本，迫使製造商重新评估筹资策略和成本转嫁方式。为此，许多公司加快了替代供应商的认证进程，考虑将製造地迁至更靠近需求中心的地方，并扩大产能以降低关税风险。

透过对动物种类、疫苗技术、给药途径、疾病类别和最终用户进行详细的細項分析，揭示了有针对性的机会和风险。

市场区隔为将宏观趋势转化为针对特定动物种类、平台、给药途径、疾病和最终用途的策略提供了切实可行的观点。就动物种类而言，市场涵盖水产养殖、牛、伴侣动物、马、家禽和猪，其中伴侣动物又细分为猫狗。每个子类别都有其独特的购买动机、给药模式和监管途径，因此都需要相应的商业化策略。就疫苗技术而言，目前可用的平台包括结合疫苗、灭活疫苗、减毒活病毒疫苗、重组疫苗、次单元疫苗和类毒素疫苗。每种技术在生产复杂性、低温运输要求和疗效差异方面都存在权衡，因此需要不同的定价和实证策略。给药途径（注射、鼻腔、口服）影响疫苗的扩散曲线和给药成本，而非侵入性给药途径则为大规模生产系统减轻劳动力负担提供了机会。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和比较优势揭示了需求模式、製造地和法规环境。

区域趋势对製造地地点、监管合规计画和打入市场策略等策略选择有显着影响。在美洲，需求主要集中在伴侣动物照护和商业牲畜的生物安全方面，这得益于成熟的经销网络和兽医服务业。法规环境特点是核准流程结构完善，但对临床和安全资料的要求很高。在欧洲、中东和非洲地区，区域差异是一大挑战。西欧对高端伴侣动物产品和先进的动物福利标准有着很高的需求，而其他次区域则呈现出不同的监管能力和疾病流行程度，因此需要灵活的註册和证据策略。在亚太地区，水产养殖的快速增长以及家禽和生猪生产的集约化带来了巨大的商机，但企业必须应对不同的管理体制、当地的生产奖励，以及某些市场对本地生产解决方案日益增长的偏好。

动物疫苗产业的竞争格局以及主要企业和创新者在伙伴关係、併购活动、产能投资和平台差异化方面采取的策略性倡议。

动物疫苗市场的竞争格局由两大构面构成：规模与创新。成熟的动物用药品公司在分销网络、监管专业知识和大规模生产能力方面保持优势，使其能够服务于包括大规模农业企业和全球连锁兽医院在内的广泛终端用户。然而，随着小规模生物技术公司和平台创新者开发出能够提高疫苗效力、安全性和易用性的重组构建体、载体疫苗和新型佐剂系统，它们的影响力正在不断增强。合约研发生产机构（CDMO）在帮助成熟企业和新参与企业扩大生产规模方面发挥着至关重要的作用，使它们无需投入大量资金来拥有完整的生产设施。

为产业领导者提供切实可行的策略建议，以利用技术、供应链韧性、监管合作和以客户为中心的商业化方法。

领导者应在技术、供应链、监管和商业化等方面采取果断行动，将市场复杂性转化为竞争优势。优先投资于能够实现抗原柔软性和可扩展生产的平台技术，缩短概念验证研发週期，并专注于能够快速应对不断变化的病原体情况的重组和模组化方法。同时，应实现关键原材料供应商网路的多元化，并制定紧急时应对计画，包括经认证的替代来源和灵活的生产结构，以应对地缘政治因素和关税相关的干扰。

严谨的调查方法说明：一手访谈、二手资讯、监管与专利分析、临床证据评估、以及多方面的资料匹配方法。

本分析所依据的研究整合了定性和定量信息，以确保其可靠性和可操作性。主要研究包括对疫苗研发公司的高阶主管、生产负责人和监管专家，以及大型终端使用者（例如综合农业企业和多站点兽医诊所）进行结构化访谈。次要分析则利用了同行评审文献、监管指导文件、临床试验註册信息、专利申请和公开的公司信息，以验证相关趋势并检验有关技术成熟度和商业性趋势的说法。供应链图谱和情境分析用于评估贸易政策变化的影响，并评估关税相关变化对采购的影响。

概述兽用疫苗领域在应对技术变革、贸易逆风和不断变化的终端用户期望方面所面临的风险、策略机会和优先事项。

总之，兽用疫苗产业正处于策略转折点，科学创新、政策趋势和不断变化的终端用户期望在此交汇，亟需重塑竞争优势。抗原设计和平台柔软性的技术进步为伴侣动物、家畜和水产养殖的疾病管理开闢了新途径，而贸易和关税压力则凸显了供应链韧性和适应性筹资策略的必要性。基于动物种类、疫苗技术、给药途径、目标疾病和终端用户背景的细分，为优先投资和定製商业化计划提供了一个切实可行的框架。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 兽用与动物疫苗市场：依产品类型划分

  • 活病毒疫苗
  • 灭活疫苗
  • 次单元疫苗和重组疫苗
  • 病毒载体疫苗

第九章 兽用及动物疫苗市场：依给药途径划分

  • 肠外
  • 口服
  • 外用

第十章 兽用及动物疫苗市场：依目标疾病划分

  • 病毒性疾病
    • 狂犬病
    • 口蹄疫
    • 新城疫
    • 犬小病毒
    • 犬瘟热
    • 猫泛白血球减少症
    • 传染性牛鼻气管炎
  • 细菌性疾病
    • 布氏桿菌症
    • 钩端螺旋体病
    • 梭状菌感染
    • 巴氏桿菌症
    • 大肠桿菌感染
  • 寄生虫病
  • 霉菌感染疾病

第十一章 兽用及动物疫苗市场：依技术平台划分

  • 传统疫苗
  • 先进疫苗
  • 新的配送系统

第十二章 兽用与动物疫苗市场：依价态划分

  • 单价疫苗
  • 多价疫苗

第十三章 兽用与动物疫苗市场：依动物类型划分

  • 伴侣动物
    • 狗
    • 猫
    • 马
  • 肉类动物
    • 牛
    • 猪
    • 家禽
    • 绵羊/山羊
    • 水产养殖
  • 野生动物和动物园动物

第十四章 兽用及动物疫苗市场：依通路划分

  • 动物医院
  • 零售药房
  • 网路药房

第十五章 兽用与动物疫苗市场：依最终用户划分

  • 兽医医院和诊所
  • 畜牧场及生产设施
  • 测试机构
  • 研究机构和大学
  • 政府和公共卫生机构

第十六章 兽用及动物疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章 兽用及动物疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章 兽药与动物疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国：兽药和动物疫苗市场

第二十章：中国：兽药和动物疫苗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Arko Corp.
  • Bimeda Biologicals Inc
  • Biogenesis Bago SA
  • Biogenesis Bago SA
  • Bioveta, as
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Endovac Animal Health
  • Hester Biosciences Limited
  • Hipra SA
  • Huvepharma, Inc.
  • Indian Immunologicals Limited
  • Indian Immunologicals Ltd.
  • Jinyu Bio-technology Co., Ltd.
  • Kemin Industries, Inc.
  • Merck & Co., Inc.
  • MEVAC
  • Neogen Corporation
  • Nisseiken Co., Ltd.
  • Pfizer, Inc.
  • Phibro Animal Health Corporation
  • Qingdao Yebio Biological Engineering Co., Ltd.
  • SAN Group
  • Seppic by Air Liquide Healthcare
  • SK Bioscience
  • Vaxxinova
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-034B500303A8

The Veterinary/Animal Vaccines Market was valued at USD 15.05 billion in 2025 and is projected to grow to USD 16.05 billion in 2026, with a CAGR of 6.89%, reaching USD 24.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.05 billion
Estimated Year [2026] USD 16.05 billion
Forecast Year [2032] USD 24.01 billion
CAGR (%) 6.89%

Comprehensive overview of the veterinary vaccines landscape revealing key drivers, stakeholder roles, technological progress, and regulatory interactions shaping strategies

The veterinary vaccines domain is in the midst of a structural transformation that is altering scientific paradigms, commercial strategies, and the operational footprints of manufacturers and service providers. Stakeholders across research institutions, clinical practice, farming operations, and regulatory bodies are converging around shared objectives: improved disease control, enhanced animal welfare, and resilient supply chains. As the scientific base expands to include advanced immunology platforms and digital health tools, the roles of vaccine developers and distributors are evolving from pure product suppliers to integrated partners offering end-to-end prevention and surveillance solutions.

Moreover, regulatory systems are increasingly harmonized in principle but remain heterogeneous in practice, prompting firms to design regulatory strategies that balance regional compliance with global scalability. Concurrently, consumer and producer expectations for safety, traceability, and sustainability are raising the bar for product evidence and lifecycle transparency. Taken together, these dynamics demand strategic clarity: organizations must prioritize platform investments, cultivate cross-sector partnerships, and align commercial models with shifting end-user behaviors. This introduction sets the stage for an evidence-driven exploration of how technological advances, trade dynamics, and market segmentation intersect to create both immediate challenges and durable opportunities in the veterinary vaccines landscape.

How transformative scientific breakthroughs, platform innovations, and shifting stakeholder priorities are redefining vaccine development, delivery, and adoption across species

The last decade has seen several transformative shifts that are recalibrating how vaccines are discovered, produced, delivered, and adopted across animal health sectors. A significant scientific shift is the maturation of platform technologies that accelerate antigen discovery and enable modular vaccine constructs; these platforms shorten development cycles and facilitate rapid responses to emergent pathogens. In parallel, precision livestock farming and digital surveillance systems are generating higher-resolution epidemiological data, creating feedback loops that inform vaccine design and deployment strategies more rapidly than before.

Commercially, there is a pronounced pivot toward value-based propositions that emphasize disease prevention economics, herd health optimization, and integrated service offerings-moving beyond transactional sales of products to subscription-style or outcome-oriented contracts. Supply chains are being redesigned for resilience: strategic nearshoring, capacity redundancy, and diversified supplier networks are becoming standard risk mitigants. Regulatory evolution is also notable, with some jurisdictions experimenting with streamlined pathways for novel platforms while maintaining rigorous safety and efficacy standards. These converging shifts mean that organizations able to integrate scientific agility, data-driven decision-making, and robust commercial models will gain disproportionate advantage. Consequently, leaders must align R&D priorities, manufacturing investments, and stakeholder engagement to capture the upside of these structural transitions.

Analyzing the cumulative effects of United States tariff policies in 2025 on supply chains, manufacturing choices, pricing dynamics, and global trade patterns for animal vaccines

United States tariff policy adjustments in 2025 introduced a layer of trade complexity that reverberated across global supply chains and procurement strategies in the animal health sector. The cumulative effect increased imported input costs for raw biological materials, specialized reagents, and equipment used in vaccine manufacturing, prompting manufacturers to reassess sourcing strategies and cost pass-through approaches. In response, many firms expedited qualification of alternative suppliers and evaluated relocation or expansion of manufacturing capacity closer to demand centers to mitigate tariff exposure.

These shifts also influenced commercial pricing negotiations and contract structures with distributors and large purchasers such as integrated producers and veterinary chains. Procurement teams sought greater transparency around landed costs and inventory planning, which in turn pushed manufacturers to strengthen supply chain analytics and scenario planning capabilities. Trade diversion patterns emerged as companies shifted procurement to tariff-favored partners, yet such reconfiguration created secondary risks including longer qualification timelines, variable supplier quality, and the need for additional regulatory filings.

From a strategic perspective, the tariff environment accelerated two durable trends: the economics of localized manufacturing for strategic SKUs and the emphasis on building supplier redundancy for critical inputs. Firms that had previously invested in flexible manufacturing platforms found it easier to adapt production mixes and maintain supply continuity. Looking ahead, organizations must continue to refine sourcing strategies, engage proactively with trade and regulatory stakeholders, and structure commercial agreements that recognize the potential for future policy shocks while preserving customer access to essential vaccines.

Deep segmentation insights across animal types, vaccine technologies, administration routes, disease categories, and end users to uncover targeted opportunities and risks

Segmentation offers a practical lens to translate macro trends into targeted strategies by species, platform, administration route, disease, and end-use context. When considering animal type, the market spans aquaculture, cattle, companion animals, equine, poultry, and swine with companion animals further dissected into cats and dogs-each subcategory exhibits distinct purchase drivers, dosing paradigms, and regulatory pathways that demand tailored commercialization approaches. On vaccine technology, choices range from conjugate, killed/inactivated, live attenuated, recombinant, subunit, to toxoid platforms; each technology carries trade-offs in manufacturing complexity, cold-chain demands, and differentiating claims, and therefore requires distinct pricing and evidentiary strategies. Route of administration-injectable, nasal, and oral-shapes adoption curves and administration cost profiles, with noninvasive routes presenting opportunities to lower labor burdens in mass production systems.

Disease type segmentation across bacterial, parasitic, and viral targets informs R&D prioritization and surveillance investments since pathogen biology and epidemiology dictate the feasibility of sterilizing immunity versus disease mitigation. Finally, end-user segmentation across clinics, farms, and veterinary hospitals-with farms further delineated into aquaculture farms, cattle farms, equine facilities, poultry farms, and swine farms-clarifies distribution channels and after-sales service needs; for example, aquaculture and poultry operations emphasize bulk dosing logistics and administration technologies, while clinics and veterinary hospitals prioritize companion animal brands, safety profiles, and client communication tools. Integrating these segmentation perspectives enables firms to design portfolio strategies that match product attributes with user willingness to pay, operational constraints, and regulatory requirements, thereby improving product uptake and lifecycle management.

Regional dynamics and comparative advantages across the Americas, Europe Middle East and Africa, and Asia-Pacific revealing demand patterns, manufacturing hubs, and regulatory climates

Regional dynamics materially shape strategic choices in manufacturing footprint, regulatory planning, and go-to-market approaches. In the Americas, demand is disproportionately weighted toward companion animal care and commercial livestock biosecurity, supported by established distribution networks and a mature veterinary services sector; the regulatory environment is characterized by well-developed pathways but significant expectations for clinical and safety data. In Europe, Middle East & Africa, heterogeneity is the primary challenge: Western Europe displays high demand for premium companion animal products and progressive animal welfare standards, while other subregions feature variable regulatory capacity and differing disease prevalence that call for adaptable registration and evidence strategies. In the Asia-Pacific region, rapid growth of aquaculture and intensification of poultry and swine production present large-scale opportunities, but companies must navigate diverse regulatory regimes, local manufacturing incentives, and a rising preference for locally produced solutions in some markets.

These regional contrasts suggest distinct investment priorities: Americas-focused strategies emphasize branding, data-driven value propositions for clinics and veterinary hospitals, and integrated customer engagement; Europe, Middle East & Africa requires flexible regulatory teams and tailored market-access plans; Asia-Pacific calls for scalable production options, partnerships with local players, and disease surveillance investments that reflect regional burden. Firms that harmonize global R&D platforms with region-specific commercialization playbooks will achieve faster adoption and higher operational efficiency across these three broad territories.

Competitive landscape and strategic moves by leading companies and innovators shaping partnerships, M&A activity, capacity investments, and platform differentiation in animal vaccines

Competitive dynamics in veterinary vaccines are characterized by a dual axis of scale and innovation. Established animal health companies retain advantages in distribution reach, regulatory expertise, and large-scale manufacturing capacity, enabling them to serve broad end-user bases such as major farming operations and global veterinary chains. However, smaller biotechnology firms and platform innovators are increasingly influential, pioneering recombinant constructs, vectored vaccines, and novel adjuvant systems that can improve efficacy, safety, and administration convenience. Contract development and manufacturing organizations (CDMOs) play an outsized role by enabling both incumbents and new entrants to scale production without the capital intensity of owning end-to-end facilities.

Strategic behaviors include targeted M&A to fill capability gaps, co-development partnerships to accelerate platform validation, and licensing arrangements that regionalize manufacturing while protecting core IP. Companies that emphasize platform flexibility and modular manufacturing gain the ability to pivot across antigens and species rapidly, creating competitive insulation against demand swings. Additionally, firms investing in field-level support-such as cold-chain solutions, training programs for on-farm administration, and digital monitoring tools-differentiate themselves by reducing adoption friction. In sum, the competitive battleground is shifting from single-product propositions to integrated solutions that combine scientific differentiation with operational excellence and customer-centric services.

Actionable strategic recommendations for industry leaders to capitalize on technology, supply chain resilience, regulatory engagement, and customer-centric commercialization approaches

Leaders should act decisively across technology, supply chain, regulatory, and commercial dimensions to convert market complexity into competitive advantage. Prioritize investment in platform technologies that enable antigen agility and scalable production, focusing on recombinant and modular approaches that reduce time to proof-of-concept and allow rapid response to shifting pathogen landscapes. Simultaneously, diversify supplier networks for critical inputs and develop contingency plans that include qualified alternate sources and flexible manufacturing arrangements to withstand geopolitical and tariff-related disruptions.

Strengthen regulatory engagement by allocating resources to harmonize dossiers across major territories and by participating in policy dialogues that shape accelerated pathways for novel platforms. Commercially, tailor go-to-market models to segmentation realities: cultivate relationships with clinics and veterinary hospitals for companion animal adoption, and design bulk dosing and administration solutions for farms, including aquaculture farms, poultry farms, cattle farms, equine facilities, and swine farms. Leverage digital tools for surveillance, post-market evidence generation, and customer support to build trust and demonstrate outcomes. Finally, pursue strategic collaborations with contract manufacturers, academic partners, and local market leaders to combine scale with innovation while preserving optionality and speed to market.

Rigorous research methodology describing primary interviews, secondary sources, regulatory and patent analysis, clinical evidence appraisal, and multi-source data triangulation approach

The research underpinning this analysis synthesized qualitative and quantitative inputs to ensure robustness and practical relevance. Primary research included structured interviews with senior executives across vaccine developers, manufacturing leaders, regulatory experts, and large end users such as integrated farming operations and multi-site veterinary practices. Secondary analysis drew on peer-reviewed literature, regulatory guidance documents, clinical trial registries, patent filings, and public corporate disclosures to triangulate trends and validate claims about technological readiness and commercial behavior. Supply chain mapping and scenario analysis were used to assess exposure to trade policy shifts and to evaluate the implications of tariff-driven sourcing pivots.

Data integrity was maintained through cross-validation across multiple independent sources and by testing alternative hypotheses during expert workshops. Where gaps existed, targeted follow-up interviews and vendor discussions were commissioned to ensure clarity on manufacturing timelines, platform capabilities, and regional regulatory nuances. The methodological approach balances depth and transparency, enabling stakeholders to understand both the evidence basis for conclusions and the practical implications for strategic planning, risk management, and investment prioritization.

Concluding synthesis of risks, strategic opportunities, and priority actions to navigate technological change, trade headwinds, and evolving end-user expectations in veterinary vaccines

In conclusion, the veterinary vaccines sector stands at a strategic inflection point where scientific innovation, policy dynamics, and evolving end-user expectations converge to reshape competitive advantage. Technological advances in antigen design and platform flexibility open new avenues for disease control across companion animals, livestock, and aquaculture, while trade and tariff pressures underscore the need for supply chain resilience and adaptive sourcing strategies. Segmentation across animal types, vaccine technologies, routes of administration, disease targets, and end-user contexts provides a pragmatic framework for prioritizing investments and customizing commercialization plans.

Executives who align R&D pipelines with operational agility, who invest in multi-regional regulatory competency, and who forge partnerships that combine scientific differentiation with manufacturing scale will be best positioned to capture long-term value. The pathways forward favor organizations that think systemically-integrating surveillance, vaccination programs, and post-market evidence generation-to deliver demonstrable outcomes for animal health, producer economics, and public health objectives. With disciplined execution and strategic foresight, stakeholders can convert current disruptions into durable competitive advantages.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary/Animal Vaccines Market, by Product Type

  • 8.1. Live Attenuated Vaccines
  • 8.2. Inactivated Vaccines
  • 8.3. Subunit & Recombinant Vaccines
  • 8.4. Viral Vector Vaccines

9. Veterinary/Animal Vaccines Market, by Route Of Administration

  • 9.1. Parenteral
  • 9.2. Oral
  • 9.3. Topical

10. Veterinary/Animal Vaccines Market, by Disease Indication

  • 10.1. Viral Diseases
    • 10.1.1. Rabies
    • 10.1.2. Foot-and-Mouth Disease
    • 10.1.3. Newcastle Disease
    • 10.1.4. Canine Parvovirus
    • 10.1.5. Canine Distemper
    • 10.1.6. Feline Panleukopenia
    • 10.1.7. Infectious Bovine Rhinotracheitis
  • 10.2. Bacterial Diseases
    • 10.2.1. Brucellosis
    • 10.2.2. Leptospirosis
    • 10.2.3. Clostridial Infections
    • 10.2.4. Pasteurellosis
    • 10.2.5. Colibacillosis
  • 10.3. Parasitic Diseases
  • 10.4. Fungal Infections

11. Veterinary/Animal Vaccines Market, by Technology Platform

  • 11.1. Conventional Vaccines
  • 11.2. Advanced Vaccines
  • 11.3. Novel Delivery Systems

12. Veterinary/Animal Vaccines Market, by Valency

  • 12.1. Monovalent Vaccines
  • 12.2. Multivalent Vaccines

13. Veterinary/Animal Vaccines Market, by Animal Type

  • 13.1. Companion Animals
    • 13.1.1. Dogs
    • 13.1.2. Cats
    • 13.1.3. Horses
  • 13.2. Food-Producing Animals
    • 13.2.1. Cattle
    • 13.2.2. Swine
    • 13.2.3. Poultry
    • 13.2.4. Sheep & Goats
    • 13.2.5. Aquaculture
  • 13.3. Wildlife & Zoo Animals

14. Veterinary/Animal Vaccines Market, by Distribution Channel

  • 14.1. Veterinary Clinics
  • 14.2. Retail Pharmacies
  • 14.3. Online Pharmacies

15. Veterinary/Animal Vaccines Market, by End User

  • 15.1. Veterinary Hospitals & Clinics
  • 15.2. Animal Farms & Production Units
  • 15.3. Reference Laboratories
  • 15.4. Research Institutes & Universities
  • 15.5. Government & Public Health Agencies

16. Veterinary/Animal Vaccines Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Veterinary/Animal Vaccines Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Veterinary/Animal Vaccines Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Veterinary/Animal Vaccines Market

20. China Veterinary/Animal Vaccines Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Arko Corp.
  • 21.6. Bimeda Biologicals Inc
  • 21.7. Biogenesis Bago S.A.
  • 21.8. Biogenesis Bago S.A.
  • 21.9. Bioveta, a.s.
  • 21.10. Boehringer Ingelheim International GmbH
  • 21.11. Ceva Sante Animale
  • 21.12. Dechra Pharmaceuticals PLC
  • 21.13. Elanco Animal Health Incorporated
  • 21.14. Endovac Animal Health
  • 21.15. Hester Biosciences Limited
  • 21.16. Hipra S.A.
  • 21.17. Huvepharma, Inc.
  • 21.18. Indian Immunologicals Limited
  • 21.19. Indian Immunologicals Ltd.
  • 21.20. Jinyu Bio-technology Co., Ltd.
  • 21.21. Kemin Industries, Inc.
  • 21.22. Merck & Co., Inc.
  • 21.23. MEVAC
  • 21.24. Neogen Corporation
  • 21.25. Nisseiken Co., Ltd.
  • 21.26. Pfizer, Inc.
  • 21.27. Phibro Animal Health Corporation
  • 21.28. Qingdao Yebio Biological Engineering Co., Ltd.
  • 21.29. SAN Group
  • 21.30. Seppic by Air Liquide Healthcare
  • 21.31. SK Bioscience
  • 21.32. Vaxxinova
  • 21.33. Virbac S.A.
  • 21.34. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBUNIT & RECOMBINANT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL VECTOR VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOT-AND-MOUTH DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NEWCASTLE DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE PARVOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE PARVOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE PARVOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE DISTEMPER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE DISTEMPER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CANINE DISTEMPER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FELINE PANLEUKOPENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FELINE PANLEUKOPENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FELINE PANLEUKOPENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INFECTIOUS BOVINE RHINOTRACHEITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INFECTIOUS BOVINE RHINOTRACHEITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY INFECTIOUS BOVINE RHINOTRACHEITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BRUCELLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BRUCELLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BRUCELLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY LEPTOSPIROSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CLOSTRIDIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PASTEURELLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PASTEURELLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PASTEURELLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COLIBACILLOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COLIBACILLOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COLIBACILLOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FUNGAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONVENTIONAL VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONVENTIONAL VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CONVENTIONAL VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ADVANCED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ADVANCED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ADVANCED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NOVEL DELIVERY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NOVEL DELIVERY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY NOVEL DELIVERY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MONOVALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MONOVALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MONOVALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY MULTIVALENT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY HORSES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY HORSES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY HORSES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SHEEP & GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SHEEP & GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SHEEP & GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY WILDLIFE & ZOO ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY WILDLIFE & ZOO ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY WILDLIFE & ZOO ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL FARMS & PRODUCTION UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL FARMS & PRODUCTION UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL FARMS & PRODUCTION UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES & UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES & UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY RESEARCH INSTITUTES & UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. GLOBAL VETERINARY/ANIMAL VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 277. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 278. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 279. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 280. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 281. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 282. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 284. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 285. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. GCC VETERINARY/ANIMAL VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VIRAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY BACTERIAL DISEASES, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY VALENCY, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY COMPANION ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET SIZE, BY FOOD-PRODUCING ANIMALS, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION VETERINARY/ANIMAL VACCINES MARKET